Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003

Clinical Microbiology and Infection

Volumn 11, Issue 12, 2005, Pages 985-991

  Reinert, R R ^a   Haupts, S ^a   van der Linden, M ^a   Heeg, C ^a   Cil, M Y ^a   Al Lahham, A ^a   Fedson, D S ^b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Sergy Haut   (France)

Author keywords

Clarithromycin; Community acquired pneumonia; Penicillin G; Resistance; Serotypes; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; GATIFLOXACIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; FREQUENCY ANALYSIS; GERMANY; HUMAN; INCIDENCE; INFECTION RISK; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEROTYPE; STREPTOCOCCUS INFECTION;

BACTERIA (MICROORGANISMS); PNEUMOCOCCUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 28644443964     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01282.x     Document Type: Article

References (32)

1. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992; 14: 801-807.
2. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 2004; 529-588.
3. Ständigelmpfkommission. Impfempfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 2001; 28: 203-218.
4. French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J Infect 2003; 46: 78-86.
5. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19: 353-363.
6. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-946.
7. Saha SK, Rikitomi N, Biswas D et al. Serotypes of Streptococcus pneumoniae causing invasive childhood infections in Bangladesh, 1992 to 1995. J Clin Microbiol 1997; 35: 785-787.
8. Reinert RR. Pneumococcal conjugate vaccines - a European perspective. Int J Med Microbiol 2004; 294: 277-294.
9. von Kries R, Siedler A, Schmitt HJ et al. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 2000; 31: 482-487.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 14th informational supplement. M100-S14. Wayne, PA: NCCLS, 2004.
11. Montanari MP, Mingoia M, Giovanetti E et al. Differentiation of resistance phenotypes among erythromycin-resistant pneumococci. J Clin Microbiol 2001; 39: 1311-1315.
12. Reinert RR, Al-Lahham A, Lemperle M et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-68.
13. Reinert RR, Lütticken R, Bryskier A et al. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003; 47: 489-493.
14. Reinert RR, Ringelstein A, van der Linden M et al. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. J Clin Microbiol 2005; 43: 1294-1300.
15. Stephens DS, Zughaier SM, Whitney CG et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365: 855-863.
16. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
17. de la Campa AG, Balsalobre L, Ardanuy C et al. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis 2004; 10: 1751-1759.
18. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002; 34: 1613-1620.
19. Mandell LA, Bartlett JG, Dowell SF et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
20. Vogel F, Scholz H. PEG-Empfehlungen: rationaler einsatz oraler antibiotika bei erwachsenen. Chemother J 2002; 2: 47-58.
21. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-2326.
22. Reinert RR, Queck A, Kaufhold A et al. Antimicrobial resistance and type distribution of Streptococcus pneumoniae in Germany, 1992-1944. Clin Infect Dis 1995; 21: 1398-1401.
23. Felmingharn D, Reinert RR, Hirakata Y et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002; 50(suppl S1): 25-37.
24. Cars O, Molstad S, Melander A, Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851-1853.
25. Harbarth S, Albrich W, Brun-Buisson C. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis 2002; 8: 1460-1467.
26. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-587.
27. Brueggemann AB, Spratt BG. Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates. J Clin Microbiol 2003; 41: 4966-4970.
28. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35: 547-555.
29. D'Ancona F, Salmaso S, Barale A et al. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 2005; 23: 2494-2500.
30. Rüggeberg JU, Ketteler K, MacKenzie CR et al. Blood culture sampling rates at a German pediatric university hospital and incidence of invasive pneumococcal disease. Infection 2004; 32: 78-81.
31. Ament A, Baltussen R, Duru G et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000; 31: 444-450.
32. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001; 357: 950-952.